Takeda/Millennium’s Phase III IBD Drug Promises Improved Safety
This article was originally published in PharmAsia News
Executive Summary
Millennium Pharmaceuticals, which in this case could call itself "The Takeda Gastroenterology Company," announced Jan. 22 that it has launched Phase III trials of its anti-inflammatory biologic MLN0002 in two kinds of inflammatory bowel disease
You may also be interested in...
Japanese Takeda Buys Abbott’s Stake In TAP Joint U.S. Venture
Japanese drug maker Takeda will establish Takeda America Holdings after finalizing a deal March 19 to obtain a 100 percent stake in TAP Pharmaceutical Products, its 50/50 joint venture with Abbott
Millennium Initiates New Clinical Program For Ulcerative Colitis Candidate
Program includes Phase II dose-ranging study and Phase I study in healthy volunteers.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).